Stéphanie Rouanet

2.1k total citations
57 papers, 1.4k citations indexed

About

Stéphanie Rouanet is a scholar working on Cardiology and Cardiovascular Medicine, Rheumatology and Surgery. According to data from OpenAlex, Stéphanie Rouanet has authored 57 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 14 papers in Rheumatology and 13 papers in Surgery. Recurrent topics in Stéphanie Rouanet's work include Acute Myocardial Infarction Research (10 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Stéphanie Rouanet is often cited by papers focused on Acute Myocardial Infarction Research (10 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Stéphanie Rouanet collaborates with scholars based in France, Switzerland and United States. Stéphanie Rouanet's co-authors include Bernard Combe, Jean Sibilia, Xavier Le Loët, Éric Vicaut, Éric Van Belle, Xavier Mariette, Jacques Tébib, Maxime Dougados, Jean Dallongeville and G Montalescot and has published in prestigious journals such as Gastroenterology, Journal of the American College of Cardiology and European Heart Journal.

In The Last Decade

Stéphanie Rouanet

54 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stéphanie Rouanet France 22 457 456 300 230 194 57 1.4k
B. A. C. Dijkmans Netherlands 13 320 0.7× 1.5k 3.3× 238 0.8× 152 0.7× 394 2.0× 24 1.9k
Sharon Van Doornum Australia 18 345 0.8× 898 2.0× 77 0.3× 218 0.9× 322 1.7× 35 1.4k
C. S. Crowson United States 16 258 0.6× 905 2.0× 63 0.2× 320 1.4× 147 0.8× 26 1.6k
Alessandro Giollo Italy 21 138 0.3× 557 1.2× 81 0.3× 101 0.4× 211 1.1× 90 1.5k
Masayuki Yamanouchi Japan 23 116 0.3× 281 0.6× 79 0.3× 271 1.2× 151 0.8× 195 2.1k
Tracey E. Toms United Kingdom 23 381 0.8× 1.0k 2.3× 76 0.3× 180 0.8× 247 1.3× 33 1.5k
Spyros Aslanidis Greece 20 164 0.4× 441 1.0× 89 0.3× 171 0.7× 173 0.9× 45 1.0k
Rohini K. Hernandez United States 21 134 0.3× 209 0.5× 181 0.6× 340 1.5× 58 0.3× 67 1.7k
Carlos González‐Juanatey Spain 21 275 0.6× 849 1.9× 53 0.2× 149 0.6× 507 2.6× 100 1.6k
Alexandra N. Colebatch United Kingdom 10 135 0.3× 795 1.7× 58 0.2× 273 1.2× 193 1.0× 12 1.2k

Countries citing papers authored by Stéphanie Rouanet

Since Specialization
Citations

This map shows the geographic impact of Stéphanie Rouanet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Rouanet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Rouanet more than expected).

Fields of papers citing papers by Stéphanie Rouanet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Rouanet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Rouanet. The network helps show where Stéphanie Rouanet may publish in the future.

Co-authorship network of co-authors of Stéphanie Rouanet

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Rouanet. A scholar is included among the top collaborators of Stéphanie Rouanet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Rouanet. Stéphanie Rouanet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Charpentier, Etienne, Michel Zeitouni, Samia Boussouar, et al.. (2025). Epicardial adipose tissue from computed tomography: a missing link in premature coronary artery disease?. European Heart Journal - Cardiovascular Imaging. 26(4). 725–732. 1 indexed citations
2.
Procopi, Niki, Nassim Braik, Alain Combes, et al.. (2025). Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock. European Heart Journal - Cardiovascular Pharmacotherapy. 11(6). 489–499. 1 indexed citations
3.
Procopi, Niki, Mathieu Kernéis, Paul Guedeney, et al.. (2024). Ten-year trends in characteristics, management and outcomes of patients admitted with cardiogenic shock in the ACTION-SHOCK cohort. Archives of cardiovascular diseases. 117(10). 569–576. 3 indexed citations
4.
5.
Guedeney, Paul, Julio I. Farjat‐Pasos, Vincent Roule, et al.. (2023). Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure. European Heart Journal. 44(Supplement_2). 1 indexed citations
6.
Zeitouni, Michel, Niki Procopi, Paul Guedeney, et al.. (2022). Beta-blocker prescription and outcomes in uncomplicated acute myocardial infarction: Insight from the ePARIS registry. Archives of cardiovascular diseases. 116(1). 25–32. 4 indexed citations
7.
Hermida, Alexis, Véronique Fressart, Françoise Hidden‐Lucet, et al.. (2019). High Risk of Heart Failure Associated with Desmoglein-2 Mutations Compared to Plakophilin-2 Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. European Journal of Heart Failure. 21(6). 792–800. 42 indexed citations
8.
Bastard, Jean‐Philippe, Soraya Fellahi, Jacqueline Capeau, et al.. (2019). Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open. 5(2). e000897–e000897. 16 indexed citations
9.
Belle, Arthur, Emmanuel Gizard, Guillaume Conroy, et al.. (2016). 25‐OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV‐infected patients. United European Gastroenterology Journal. 5(1). 69–75. 10 indexed citations
10.
Saraux, Alain, Stéphanie Rouanet, René‐Marc Flipo, et al.. (2016). Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study.. PubMed. 34(2). 303–10. 13 indexed citations
11.
Gossec, Laure, et al.. (2015). Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.. PubMed. 33(5). 664–70. 32 indexed citations
12.
13.
14.
Chapurlat, Roland, Michel Laroche, Thierry Thomas, et al.. (2012). Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia—a randomized placebo-controlled trial. Osteoporosis International. 24(1). 311–320. 42 indexed citations
15.
Chevaliez, Stéphane, Christophe Hézode, Alexandre Soulier, et al.. (2011). High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial). Gastroenterology. 141(1). 119–127. 23 indexed citations
16.
Sellam, Jérémie, Houria Hendel‐Chavez, Stéphanie Rouanet, et al.. (2011). B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six‐month, national, multicenter, open‐label study. Arthritis & Rheumatism. 63(4). 933–938. 118 indexed citations
17.
Roux, Christian, et al.. (2011). Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. Joint Bone Spine. 79(4). 389–392. 9 indexed citations
18.
19.
Zarski, Jean‐Pierre, Nathalie Stürm, Hervé Desmorat, et al.. (2008). 841 EFFICACY AND SAFETY OF 2 YEARS MAINTENANCE THERAPY WITH PEGINTERFERON ALPHA-2A IN CHRONIC HEPATITIS C: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (FIBROSYS). Journal of Hepatology. 48. S315–S316. 1 indexed citations
20.
Montalescot, G, et al.. (2006). STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). European Heart Journal. 28(12). 1409–1417. 239 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. A. C. Dijkmans Breakdown of academic impact, for papers by Sharon Van Doornum Breakdown of academic impact, for papers by C. S. Crowson Breakdown of academic impact, for papers by Alessandro Giollo Breakdown of academic impact, for papers by Masayuki Yamanouchi Breakdown of academic impact, for papers by Tracey E. Toms Breakdown of academic impact, for papers by Spyros Aslanidis Breakdown of academic impact, for papers by Rohini K. Hernandez Breakdown of academic impact, for papers by Carlos González‐Juanatey Breakdown of academic impact, for papers by Alexandra N. Colebatch
Rankless by CCL
2026